Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

Key Points

• Morgan Stanley raised Ultragenyx Pharmaceutical’s price target to $74 from $67 and maintained an “overweight” rating, implying approximately 192% upside from the cited $25.32 share price.
• Analyst sentiment is broadly positive: 15 analysts rate the stock a Buy and the consensus rating is “Moderate Buy,” with an average price target of $58.89.
• Ultragenyx reported better-than-expected quarterly results, including a $0.90 per-share loss versus the expected $1.22 loss and revenue of $214 million, up 28.5% year over year; however, the company remains unprofitable.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price upped by Morgan Stanley from $67.00 to $74.00 in a report released on Friday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective would indicate a potential upside of 192.26% from the company's current price.

A number of other research firms also recently issued reports on RARE. Guggenheim reduced their price objective on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Barclays lowered their target price on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, April 29th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Monday, August 10th. Finally, Royal Bank Of Canada upped their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the company an "outperform" rating in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $58.89.

Ultragenyx Pharmaceutical Stock Down 3.5%

Shares of Ultragenyx Pharmaceutical stock opened at $25.32 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $18.29 and a twelve month high of $39.89. The business has a 50-day moving average price of $28.55 and a 200-day moving average price of $24.97. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -4.34 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts' consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the business earned ($1.17) earnings per share. The firm's revenue for the quarter was up 28.5% on a year-over-year basis. On average, equities analysts expect that Ultragenyx Pharmaceutical will post -4.12 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 1,899 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the sale, the executive vice president directly owned 94,462 shares of the company's stock, valued at $2,325,654.44. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the sale, the director directly owned 21,095 shares of the company's stock, valued at $528,429.75. The trade was a 8.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,552 shares of company stock worth $207,455 over the last ninety days. Company insiders own 5.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 14.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company's stock worth $8,414,000 after purchasing an additional 29,984 shares during the period. Creative Planning purchased a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth about $454,000. American Century Companies Inc. purchased a new stake in Ultragenyx Pharmaceutical in the 2nd quarter worth about $366,000. M&T Bank Corp raised its position in Ultragenyx Pharmaceutical by 19.7% in the 2nd quarter. M&T Bank Corp now owns 7,232 shares of the biopharmaceutical company's stock worth $263,000 after purchasing an additional 1,192 shares during the period. Finally, Amundi lifted its stake in Ultragenyx Pharmaceutical by 1,560.4% in the second quarter. Amundi now owns 99,161 shares of the biopharmaceutical company's stock worth $3,913,000 after purchasing an additional 93,189 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: GENGLYCOS could expand Ultragenyx’s commercial pipeline and reduce the treatment burden for patients with GSDIa. The approval also included a Priority Review Voucher, which may have significant strategic or financial value. Reuters FDA approval report
• Positive Sentiment: The FDA decision strengthens Ultragenyx’s rare-disease portfolio and creates the potential for a long-term revenue contribution, which Wells Fargo described as a possible “long revenue tailwind.” Yahoo Finance gene-therapy analysis
• Positive Sentiment: Analysts responded favorably: Cantor Fitzgerald raised its price target to $103, Canaccord Genuity to $83, Citi to $58, and Wells Fargo to $46. Cantor, Canaccord, and Citi maintained or initiated “buy” or “overweight” ratings, implying substantial upside from the supplied $25.32 reference price.
• Neutral Sentiment: The accelerated approval is an important regulatory milestone, but commercial success will depend on launch execution, patient uptake, reimbursement, and any required confirmatory evidence. Ultragenyx remains unprofitable, with analysts expecting a full-year loss.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source